Losing participants before the trial ends erodes credibility of findings

  • J. X
  • C. A
  • N. B
  • et al.
Citations of this article
Mendeley users who have this article in their library.


AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.




J., X., C., A., N., B., V., B., P., B., H., E.-S., & V., P. (2009). Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin. J. Xia, Cochrane Schizophrenia Group, Bridge House, Balm Road, Leeds LS10 2TP. E-mail: jun.xia@nottingham.ac.uk: Royal College of Psychiatrists (17 Belgrave Square, London SW1X 8PG, United Kingdom). Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=354958081

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free